Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice

Brain Res Bull. 2019 Mar:146:279-286. doi: 10.1016/j.brainresbull.2019.01.018. Epub 2019 Jan 25.

Abstract

Clinical and pre-clinical evidences indicate an association between inflammation and depression since increased levels of pro-inflammatory cytokines are associated with depression-related symptoms. Atorvastatin is a cholesterol-lowering statin that possesses pleiotropic effects including neuroprotective and antidepressant actions. However, the putative neuroprotective effect of atorvastatin treatment in the acute inflammation mice model of depressive-like behaviour has not been investigated. In the present study, we aimed to investigate the effect of atorvastatin treatment on lipopolysaccharide (LPS) induced depressive-like behaviour in mice. Mice were treated with atorvastatin (1 or 10 mg/kg, v.o.) or fluoxetine (30 mg/kg, positive control, v.o.) for 7 days before LPS (0.5 mg/kg, i.p.) injection. Twenty four hours after LPS infusion, mice were submitted to the forced swim test, tail suspension test or open field test. After the behavioural tests, mice were sacrificed and the levels of tumour necrosis factor-α (TNF-α), brain-derived neurotrophic factor (BDNF), glutathione and malondialdehyde were measured. Atorvastatin (1 or 10 mg/kg/day) or fluoxetine treatment prevented LPS-induced increase in the immobility time in the forced swim and tail suspension tests with no alterations in the locomotor activity evaluated in the open field test. Atorvastatin (1 or 10 mg/kg/day) or fluoxetine treatment also prevented LPS-induced increase in TNF-α and reduction of BDNF levels in the hippocampus and prefrontal cortex. Treatment with atorvastatin (1 or 10 mg/kg/day) or fluoxetine prevented LPS-induced increase in lipid peroxidation and the reduction of glutathione levels in the hippocampus and prefrontal cortex. The present study suggests that atorvastatin treatment exerted neuroprotective effects against LPS-induced depressive-like behaviour which may be related to reduction of TNF-α release, oxidative stress and modulation of BDNF expression.

Keywords: Brain-derived neurotrophic factor; Depression; Lipopolysaccharide; Oxidative stress; Statins; Tumour necrosis factor-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacology
  • Atorvastatin / metabolism
  • Atorvastatin / pharmacology*
  • Behavior, Animal / drug effects
  • Brain-Derived Neurotrophic Factor / metabolism
  • Depression / chemically induced
  • Depression / drug therapy*
  • Depressive Disorder / drug therapy
  • Disease Models, Animal
  • Fluoxetine / pharmacology
  • Hippocampus / drug effects
  • Lipopolysaccharides / pharmacology
  • Male
  • Mice
  • Neuroprotective Agents / pharmacology
  • Oxidative Stress / drug effects
  • Prefrontal Cortex / drug effects
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antidepressive Agents
  • Bdnf protein, mouse
  • Brain-Derived Neurotrophic Factor
  • Lipopolysaccharides
  • Neuroprotective Agents
  • Tumor Necrosis Factor-alpha
  • Fluoxetine
  • Atorvastatin